BB Biotech AG Reports Interim Gains and Adjusts Dividend Policy

On July 24, 2026, BB Biotech AG revealed its interim report for the first half of 2026, marking a notable turnaround in its financial performance. The company achieved a net gain of CHF 430 million, contrasting significantly with a loss of CHF 341 million recorded in the same period of 2025. Notably, the second quarter alone contributed a CHF 451 million profit, a marked improvement from a CHF 100 million loss in the previous year. This performance is attributed to its investment portfolio's success.

Additionally, the company announced a revision of its dividend policy effective from the fiscal year 2026. BB Biotech will now aim for an annual dividend yield of 3-5%, moving away from its previous fixed dividend approach. The full interim report is accessible at www.bbbiotech.ch.